Fig. 7

Indomethacin enhanced the anti-tumour effects of AVE8134 in the B16F10 model and in vitro. a1 and a2 Images of B16F10 primary xenograft tumours and their growth curves in mice treated with AVE, indomethacin, or both together (n = 8). ^*P < 0.05 vs control; ^#P < 0.05 vs AVE or indomethacin. b1 and b2 Hematoxylin and eosin (HE) staining and the number of lung metastatic tumours (n = 5). ^*P < 0.05 vs placebo. c1–d2 Representative images and their histograms of capillary-like structures and cell migration at the indicated treatment (n = 8). ^*P < 0.05 vs control; ^#P < 0.05 vs AVE. e Proliferative ability of HUVECs treated with AVE, indomethacin, or both together, as assessed by BrdU incorporation (n = 6). ^*P < 0.05 vs control; ^#P < 0.01 vs AVE